Principal Investigator
Andrew Nierenberg, MD
Massachusetts General Hospital
- 2 trials
- 1 compound
Therapeutic focus
- Major Depressive Disorder
- Bipolar Depression
- Suicidal Ideas
- Suicidal Ideation
- Suicide, Attempted
All trials (2)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT03748446 | Phase 0 | Active | — | Massachusetts General Hospital |
| NCT02974010 | Phase 2 | Completed | NRX-101 (D-cycloserine/lurasidone) | NRx Pharmaceuticals, Inc. |
Compounds studied
Trial sites (5)
- Fort Lauderdale, Florida, United States
- Charlotte, North Carolina, United States
- Boston, Massachusetts, United States
- Houston, Texas, United States
- Birmingham, Alabama, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).